13 completed, 2 active not recruiting, 2 no longer available, 2 recruiting. 12 Phase 3, 7 Phase 2, 3 Phase 1, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 8, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
| Early Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Biohaven Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BHV-7000 Responsive Neurostimulation System (RNS) Study BHV-700 - Epilepsy, Seizures | Phase 1 | Completed | Yale University | 5 | 2025-10-07 | 2026-10-21 |
| A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma Troriluzole - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Ugonma Chukwueke | 27 | 2025-02-19 | 2025-09-11 |
| A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy taldefgrobep alfa, Placebo - Spinal Muscular Atrophy, Neuromuscular Diseases | Phase 3 | Active not recruiting | Biohaven Pharmaceuticals, Inc. | 269 | 2022-07-06 | 2026-06-01 |
| Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 - Multiple Myeloma | Phase 1 | Completed | Biohaven Pharmaceuticals, Inc. | 7 | 2021-10-21 | 2025-01-20 |
| Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets Ipilimumab, Nivolumab, Troriluzole - Melanoma, Metastatic Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 1 | 2021-06-30 | 2024-03-26 |
| Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder Troriluzole (BHV-4157) - Obsessive Compulsive Disorder | Phase 3 | Terminated | Biohaven Pharmaceuticals, Inc. | 772 | 2021-03-30 | 2026-02-25 |
| A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 589 | 2021-01-29 | 2026-05-22 |
| Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients [F-18]PBR06, Verdiperstat - Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant | Early Phase 1 | Completed | Brigham and Women's Hospital | 19 | 2020-12-30 | 2022-08-19 |
| Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 456 | 2020-12-22 | 2026-01-07 |
| HEALEY ALS Platform Trial - Regimen B Verdiperstat Matching Placebo, Verdiperstat - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 167 | 2020-07-28 | 2023-06-12 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-10-23 |
| Study of BHV-3241 in Participants With Multiple System Atrophy Verdiperstat, Placebo - Multiple System Atrophy | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 421 | 2019-07-29 | 2023-09-29 |
| Troriluzole in Adult Participants With Spinocerebellar Ataxia troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1 | Phase 3 | Active not recruiting | Biohaven Pharmaceuticals, Inc. | 299 | 2019-03-08 | 2026-06-24 |
| Randomized Trial of Adult Participants With Generalized Anxiety Disorder Troriluzole, Placebo - Generalized Anxiety Disorder | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 881 | 2019-02-19 | 2024-05-08 |
| Study of BHV-4157 in Alzheimer's Disease troriluzole, Placebo oral capsule - Alzheimer Disease | Phase 2 | Completed | Biohaven Pharmaceuticals, Inc. | 350 | 2018-07-31 | 2023-12-06 |
| Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS BHV-0223 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | Biohaven Pharmaceuticals, Inc. | 22 | 2018-02-02 | 2022-10-06 |
| Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder Troriluzole, Placebo - Obsessive-Compulsive Disorder | Phase 2 / Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 426 | 2017-12-19 | 2026-01-22 |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Trial in Adult Participants With Spinocerebellar Ataxia (SCA) Troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1 | Phase 2 / Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 141 | 2016-12-15 | 2025-10-08 |
| Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA) BHV3241, verdiperstat - Multiple System Atrophy (MSA) | No longer available | Biohaven Pharmaceuticals, Inc. | 2022-10-06 |
Showing 20 of 22. Sign in to see all of them.
Obsessive-Compulsive Disorder (4) · Amyotrophic Lateral Sclerosis (3) · Multiple System Atrophy (3) · Spinocerebellar Ataxias (3) · Glioblastoma (2) · Alzheimer Disease (1) · Ataxia (1) · Brain Neoplasms (1) · Epilepsy (1) · Generalized Anxiety Disorder (1) · Heart Arrest (1) · Hematologic Neoplasms (1) · Machado-Joseph Disease (1) · Melanoma (1) · Multiple Myeloma (1)
ADI PEG20 (1) · AZD1390 (1) · Dianhydrogalactitol (1) · GDC-0084 (1) · Immunoglobulins, Intravenous (1) · Interleukin-2 (1) · Ipilimumab (1) · Lomustine (1) · Nivolumab (1) · Radiation (1) · Riluzole (1) · Sugars (1) · Temozolomide (1) · regorafenib (1) · tinostamustine (1)
United States (20) · Italy (4) · United Kingdom (4) · Canada (3) · Germany (3) · Netherlands (3) · Spain (3) · China (2) · France (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Poland (1) · Switzerland (1)
Ann W Silk, MD, MS (1) · Imran Quraishi, MD, PhD (1) · Lindsey Lair, MD (1) · Merit Cudkowicz, MD (1) · Michael H. Bloch, MD, MS (1) · Tarun Singhal, MD (1) · Tim Cloughesy, MD (1) · Ugonma Chukwueke, MD (1) · Vikram Khurana, MD, PhD (1)
PMID 34115419, PMID 38773224, PMID 38814532, PMID 39462179, PMID 39806095, PMID 40067754, PMID 40317057, PMID 41980234